pillbase.ru

Lunsumio

Active substance: mosunetuzumab

mosunetuzumab

Centralised EU authorisationActive

Marketing holder: Roche Registration GmbH

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 4
  • Lunsumio
    CONCENTRATE · MOSUNETUZUMAB 1 mg/mL
    50242-159
    Genentech, Inc.
  • Lunsumio
    CONCENTRATE · MOSUNETUZUMAB 30 mg/30mL
    50242-142
    Genentech, Inc.
  • Lunsumio Velo
    INJECTION · MOSUNETUZUMAB 5 mg/.5mL
    50242-177
    Genentech, Inc.
  • Lunsumio Velo
    INJECTION · MOSUNETUZUMAB 45 mg/mL
    50242-201
    Genentech, Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-6acb-74dd-8c55-06c5c9a48067,01a1208d-3073-71c0-8aa2-f3933f170ca0,01a12093-93bb-741a-8143-d0f636a76fec,01a12096-00dd-7c00-b85b-1747df80d905;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/005680
Registration status
Active
ATC code
L01FX25
Sources
  • product · EMA · EMEA/H/C/005680 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/005680 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/005680 · Verified 2026-10-09